Jupiter Neurosciences Raises $3.6M via 11.47M Share Sale Under SEPA, Pushing Outstanding Shares to 56.5M
JUNS is trading near its 52-week low of $0.099 (8.5% above the low) on light trading volume (0.2× avg).
Summary
Jupiter Neurosciences sold 11.47 million shares for ~$3.6M under its SEPA with Yorkville, increasing outstanding shares to 56.5 million. The deeply discounted sales continue a pattern of dilutive financing amid severe financial distress.
Key Events · Financing and Capital Events · JUNS
-
11.47M Shares Sold for $3.6M
Between May 14 and July 24, 2026, Jupiter sold 11.47 million shares to Yorkville under the SEPA, raising approximately $3.6 million in gross proceeds.
-
Deeply Discounted Pricing
Shares were sold at 97% of the lowest daily VWAP during each three-day pricing period, a structure that typically results in significant discounts to market price.
-
Outstanding Shares Surge to 56.5M
Following the sales, outstanding shares reached 56,520,143 as of July 28, 2026, representing roughly 20% dilution from the new issuance alone.
-
Ongoing Distressed Financing
This is the latest in a series of dilutive financings; the company has a going concern warning, Nasdaq delisting threat, and continues to burn cash.
Analysis · JUNS · Life Sciences
Between May 14 and July 24, 2026, Jupiter Neurosciences sold 11.47 million shares to Yorkville under its SEPA, generating approximately $3.6 million in gross proceeds. The pricing mechanism—a 3% discount to the lowest VWAP during each pricing period—creates a deeply dilutive structure. With the stock trading at $0.1075, these newly issued shares account for roughly 20% of the now 56.5 million outstanding shares, significantly eroding existing holders' stakes. This transaction extends a pattern of distressed financing as the company contends with cash burn, a going concern warning, and a Nasdaq delisting threat. While the capital provides short-term runway, it comes at a steep cost to shareholders.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JUNS was trading at $0.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.3M. The 52-week trading range was $0.10 to $1.84. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.